AlzeCure Pharma: NeuroRestore Out-Licensed in Blockbuster Deal Worth Up to USD2.2bn - Redeye

Redeye comments on AlzeCure Pharma’s signing of a landmark global out-licensing and collaboration agreement with Danish biotech QuantumCell ApS for the NeuroRestore platform, including its Phase II clinical lead asset ACD856, in a blockbuster deal worth up to USD2.2 billion.

Länk till analysen i sin helhet: https://www.redeye.se/research/1173070/alzecure-pharma-neurorestore-out-licensed-in-blockbuster-deal-worth-up-to-usd2-2bn?utm_source=finwire&utm_medium=RSS